Company intelligence / Profile preview
Anterogen Co., Ltd.
Seoul, Seoul, South Koreaanterogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Anterogen has received approval for multiple cell therapy products in South Korea, including Cupistem for Crohn's fistula and Queencell for subcutaneous adipose tissue regeneration. The company also markets Remodulin injection for pulmonary arterial hypertension. Several other programs are in clinical development phases.
- Therapeutic areas
- GastroenterologyCardiovascularRheumatologyNephrologyEndocrinologyImmunologyDermatologyNeurology
- Modalities
- Cell therapyStem cell therapyAdipose-derived stem cellsMesenchymal stem cell therapySmall molecule drug
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on Anterogen Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anterogen Co., Ltd..